Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.